Quinn T Ostrom1, Yanwen Chen1, Peter M de Blank1, Annie Ondracek1, Paul Farah1, Haley Gittleman1, Yingli Wolinsky1, Carol Kruchko1, Mark L Cohen1, Daniel J Brat1, Jill S Barnholtz-Sloan1. 1. Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Q.T.O., Y.C., H.G., Y.W., J.S.B.-S.); Central Brain Tumor Registry of the United States, Hinsdale, Illinois (Q.T.O., Y.C., H.G., Y.W., C.K., J.S.B.-S.); Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio (P.M.d.B.); The Ohio State University, Columbus, Ohio (A.O.); Case Western Reserve University, Cleveland, Ohio (P.F.); Department of Pathology, University Hospitals Case Medical Center, Cleveland, Ohio (M.L.C.); Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Emory University Hospital, Atlanta, Georgia (D.J.B.).
Abstract
BACKGROUND: Atypical teratoid/rhabdoid tumor is a rare malignant CNS tumor that most often affects children ≤ 3 years old. The Central Brain Tumor Registry of the United States contains the largest aggregation of population-based incidence data for primary CNS tumors in the US. Its data were used to describe the incidence, associated trends, and relative survival after diagnosis of atypical teratoid/rhabdoid tumor. METHODS: Using data from 50 cancer registries between 2001 and 2010, age-adjusted incidence rates per 100 000 and 95% CIs were calculated by sex, race, Hispanic ethnicity, age at diagnosis, and location of tumor in the CNS for children aged 0 to 19 years. Relative survival rates and 95% CIs were also calculated. RESULTS: The average annual age-adjusted incidence rate was 0.07 (95% CI: 0.07, 0.08). Incidence rates did not significantly vary by sex, race, or ethnicity. Age had a strong effect on incidence rate, with highest incidence among children <1 year, and decreasing incidence with increasing age. The 6-month, 1-year, and 5-year relative survival rates for all ages were 65.0%, 46.8%, and 28.3%, respectively. Atypical teratoid/rhabdoid tumor can occur anywhere in the CNS, but supratentorial tumors were more common with increasing age. CONCLUSION: We confirm differences in survival by age at diagnosis, treatment pattern, and location of tumor in the brain. This contributes to our understanding of these tumors and may stimulate research leading to improved treatment of this devastating childhood disease.
BACKGROUND: Atypical teratoid/rhabdoid tumor is a rare malignant CNS tumor that most often affects children ≤ 3 years old. The Central Brain Tumor Registry of the United States contains the largest aggregation of population-based incidence data for primary CNS tumors in the US. Its data were used to describe the incidence, associated trends, and relative survival after diagnosis of atypical teratoid/rhabdoid tumor. METHODS: Using data from 50 cancer registries between 2001 and 2010, age-adjusted incidence rates per 100 000 and 95% CIs were calculated by sex, race, Hispanic ethnicity, age at diagnosis, and location of tumor in the CNS for children aged 0 to 19 years. Relative survival rates and 95% CIs were also calculated. RESULTS: The average annual age-adjusted incidence rate was 0.07 (95% CI: 0.07, 0.08). Incidence rates did not significantly vary by sex, race, or ethnicity. Age had a strong effect on incidence rate, with highest incidence among children <1 year, and decreasing incidence with increasing age. The 6-month, 1-year, and 5-year relative survival rates for all ages were 65.0%, 46.8%, and 28.3%, respectively. Atypical teratoid/rhabdoid tumor can occur anywhere in the CNS, but supratentorial tumors were more common with increasing age. CONCLUSION: We confirm differences in survival by age at diagnosis, treatment pattern, and location of tumor in the brain. This contributes to our understanding of these tumors and may stimulate research leading to improved treatment of this devastating childhood disease.
Authors: Andrew J Bishop; Mark W McDonald; Andrew L Chang; Natia Esiashvili Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-29 Impact factor: 7.038
Authors: Adam J Fleming; Juliette Hukin; Rod Rassekh; Christopher Fryer; James Kim; Anat Stemmer-Rachamimov; Diane K Birks; Annie Huang; Stephen Yip; Christopher Dunham Journal: Brain Pathol Date: 2012-02-13 Impact factor: 6.508
Authors: Atmaram S Pai Panandiker; Thomas E Merchant; Chris Beltran; Shengjie Wu; Shelly Sharma; Frederick A Boop; Jesse J Jenkins; Kathleen J Helton; Karen D Wright; Alberto Broniscer; Larry E Kun; Amar Gajjar Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-19 Impact factor: 7.038
Authors: Katja von Hoff; Bernward Hinkes; Elke Dannenmann-Stern; André O von Bueren; Monika Warmuth-Metz; Niels Soerensen; Angela Emser; Isabella Zwiener; Paul G Schlegel; Joachim Kuehl; Michael C Frühwald; Rolf D Kortmann; Torsten Pietsch; Stefan Rutkowski Journal: Pediatr Blood Cancer Date: 2011-07-27 Impact factor: 3.167
Authors: Joanne M Hilden; Sharon Meerbaum; Peter Burger; Jonathan Finlay; Anna Janss; Bernd W Scheithauer; Andrew W Walter; Lucy B Rorke; Jaclyn A Biegel Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Susan N Chi; Mary Ann Zimmerman; Xiaopan Yao; Kenneth J Cohen; Peter Burger; Jaclyn A Biegel; Lucy B Rorke-Adams; Michael J Fisher; Anna Janss; Claire Mazewski; Stewart Goldman; Peter E Manley; Daniel C Bowers; Anne Bendel; Joshua Rubin; Christopher D Turner; Karen J Marcus; Liliana Goumnerova; Nicole J Ullrich; Mark W Kieran Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544
Authors: I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre Journal: Nature Date: 1998-07-09 Impact factor: 49.962
Authors: E Story; D L Johnston; U Bartels; A S Carret; B Crooks; D D Eisenstat; C Fryer; L Lafay-Cousin; V Larouche; B Wilson; S Zelcer; M Silva; J Brossard; E Bouffet; D L Keene Journal: J Neurooncol Date: 2017-05-16 Impact factor: 4.130
Authors: William D Foulkes; Junne Kamihara; D Gareth R Evans; Laurence Brugières; Franck Bourdeaut; Jan J Molenaar; Michael F Walsh; Garrett M Brodeur; Lisa Diller Journal: Clin Cancer Res Date: 2017-06-15 Impact factor: 12.531
Authors: Gabrielle Truitt; Haley Gittleman; Rebecca Leece; Quinn T Ostrom; Carol Kruchko; Terri S Armstrong; Mark R Gilbert; Jill S Barnholtz-Sloan Journal: J Neurooncol Date: 2019-06-17 Impact factor: 4.130